We are live on ! Find out more
XENE icon

Xenon Pharmaceuticals
XENE

159 hedge funds and large institutions have $2.37B invested in Xenon Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 59 increasing their positions, 47 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

197% more call options, than puts

Call options by funds: $15.3M | Put options by funds: $5.16M

33% more funds holding in top 10

Funds holding in top 10: 9 → 12 (+3)

29% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 17

26% more repeat investments, than reductions

Existing positions increased: 59 | Existing positions reduced: 47

21% more capital invested

Capital invested by funds: $1.96B → $2.37B (+$408M)

3% more funds holding

Funds holding: 154 → 159 (+5)

3.22% more ownership

Funds ownership: 93.36% → 96.58% (+3.2%)

Holders
159
Holders Change
+5
Holders Change %
+3.25%
% of All Funds
2.56%
Holding in Top 10
12
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+33.33%
% of All Funds
0.19%
New
22
Increased
59
Reduced
47
Closed
17
Calls
$15.3M
Puts
$5.16M
Net Calls
+$10.1M
Net Calls Change
+$14.8M

Top Buyers

Rank Fund Capital Flow
1
Loomis, Sayles & Company
Loomis, Sayles & Company
Massachusetts
+$24.7M
2
TCM
TimesSquare Capital Management
New York
+$17.6M
3
Capital International Investors
Capital International Investors
California
+$16.6M
4
LGM
Logos Global Management
California
+$14.6M
5
PCH
Polar Capital Holdings
United Kingdom
+$14M

Top Sellers

Rank Fund Capital Flow
1
Holocene Advisors
Holocene Advisors
New York
-$23.2M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$16.8M
3
Marshall Wace
Marshall Wace
United Kingdom
-$16.2M
4
ACP
Acuta Capital Partners
California
-$9.84M
5
PA
Perceptive Advisors
New York
-$7.33M
Name Holding Trade Value Shares
Change 		Change in
Stake
VCIM
101
Velan Capital Investment Management
Georgia
$789K – – –
DekaBank Deutsche Girozentrale
102
DekaBank Deutsche Girozentrale
Germany
$781K – – –
JFG
103
Jefferies Financial Group
New York
$769K +$710K +19,500 New
GC
104
Guggenheim Capital
Illinois
$753K +$151K +4,155 +28%
PHS
105
PFM Health Sciences
California
$690K +$637K +17,488 New
New York State Common Retirement Fund
106
New York State Common Retirement Fund
New York
$657K +$23.7K +650 +4%
Royal Bank of Canada
107
Royal Bank of Canada
Ontario, Canada
$636K +$587K +16,129 +1,612,900%
ERSOT
108
Employees Retirement System of Texas
Texas
$631K – – –
Legal & General Group
109
Legal & General Group
United Kingdom
$612K +$144K +3,950 +34%
Jane Street
110
Jane Street
New York
$603K -$969K -26,622 -64%
EWM
111
Elmwood Wealth Management
California
$591K – – –
SAM
112
Shell Asset Management
Netherlands
$578K -$100K -2,751 -16%
EGM
113
Engineers Gate Manager
New York
$567K +$170K +4,666 +48%
Teacher Retirement System of Texas
114
Teacher Retirement System of Texas
Texas
$557K -$30.4K -835 -6%
Handelsbanken Fonder
115
Handelsbanken Fonder
Sweden
$556K +$127K +3,500 +33%
GCP
116
GSA Capital Partners
United Kingdom
$543K +$501K +13,763 New
E
117
Ergoteles
New York
$533K +$492K +13,516 New
ASRS
118
Arizona State Retirement System
Arizona
$520K +$27.3K +750 +6%
FRM
119
Fox Run Management
Connecticut
$512K +$118K +3,244 +33%
PCM
120
Prelude Capital Management
New York
$503K +$465K +12,769 New
VRS
121
Virginia Retirement Systems
Virginia
$493K -$18.2K -500 -4%
BFM
122
Boothbay Fund Management
New York
$466K – – –
American Century Companies
123
American Century Companies
Missouri
$434K +$158K +4,335 +65%
SACTSONJ
124
Supplemental Annuity Collective Trust (SACT) of New Jersey
New Jersey
$434K – – –
Public Employees Retirement Association of Colorado
125
Public Employees Retirement Association of Colorado
Colorado
$419K – – –
3 4
5
6 7

XENE Hedge Fund Activity: Q4 2022 in Review

159 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q4 2022, worth a combined $2.37B — up 21% from $1.96B a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new XENE positions and 17 closed out — a net gain of 5 holders — while 59 added to existing stakes and 47 trimmed.

The largest buyer was Loomis, Sayles & Company, opening a new position worth an estimated $24.7M. The largest seller was Holocene Advisors, cutting an estimated $23.2M.

  • 159 institutional investors held Xenon Pharmaceuticals (XENE) as of Q4 2022, up from 154 in Q3 2022.
  • Funds reported $2.37B of Xenon Pharmaceuticals stock for Q4 2022, up 21% quarter-over-quarter.
  • 22 funds opened new Xenon Pharmaceuticals positions in Q4 2022 and 17 closed out, a net change of +5 holders.
  • The largest Xenon Pharmaceuticals buyer in Q4 2022 was Loomis, Sayles & Company, an estimated $24.7M added.
  • The largest Xenon Pharmaceuticals seller in Q4 2022 was Holocene Advisors, an estimated $23.2M sold.

Based on aggregated 13F filings for Q4 2022.